Clinical Trials

Accrual Status
Limit to SWOG Trials

1027 Results

    View
    Status Trial Number Title Activated Closed Accrual Phase Published
    Open S1900K Targeted Treatment for Advanced NSCLC that has a MET Exon 14 Skipping Gene Change 12/18/2023 0%
    Open S2213 A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab… 12/1/2023 0%
    Open S2206 A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor… 10/30/2023 1%
    Open S2210 Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency 8/14/2023 2%
    Open S2212 SCARLET 7/21/2023 5%
    Open S2207 Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment 6/30/2023 6%
    Open S2209 VRd-Lite versus DRd followedby Len+/-Dara 5/30/2023 4%
    Open S1900G Comparing Combinations of Targeted Drugs for Advanced NSCLC that has EGFR and MET Gene Changes 4/3/2023 17%
    Open S2205 ICE COMPRESS 3/16/2023 16%
    Open S2302 PRAGMATICA - LUNG 3/6/2023 64%
    Open EAY191-S3 ComboMATCH S3 3/6/2023 3%
    Open S2114 Ph II consolidation therapy following CD19 CAR-T for R/R DLBCL or Gr III FL 2/23/2023 11%
    Open S2010 ASPEN 1/17/2023 52%
    Open S2101 BiCaZO - iMATCH pilot 10/14/2022 15%
    Open S2200 S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2 9/19/2022 8%
    Open S2108CD Genomic tumor board study 8/22/2022 81%
    Closed S1900F A Randomized Phase II Study of Carboplatin and Pemetrexed With Or Without Selpercatinib In Patients With Non-Squamous RET Positive Stage IV NSCLC and Progression of Disease On Prior RET Directed Therapy 7/25/2022 6/27/2023 0%
    Open S2107 Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable… 6/6/2022 73%
    Closed S1800D LUNGMAP S1800D: Non-match Sub-Study 2/15/2022 3/10/2023 17%
    Open S2012 II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab in Patients with Poorly Differentiated Extrapulmonary Small Cell NEC 12/2/2021 23%
    Scroll Table